 Ilango Balakrishnan
Concepts (155)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glioma | 8 | 2025 | 429 | 1.560 |
Why?
| | Brain Neoplasms | 7 | 2025 | 1329 | 0.910 |
Why?
| | 12E7 Antigen | 1 | 2025 | 10 | 0.910 |
Why?
| | Medulloblastoma | 7 | 2025 | 215 | 0.820 |
Why?
| | Cerebellar Neoplasms | 6 | 2025 | 177 | 0.750 |
Why?
| | Polycomb Repressive Complex 1 | 1 | 2020 | 66 | 0.620 |
Why?
| | Antibodies, Monoclonal | 1 | 2025 | 1505 | 0.540 |
Why?
| | Cell Line, Tumor | 15 | 2025 | 3542 | 0.530 |
Why?
| | Gene Expression Regulation, Neoplastic | 9 | 2025 | 1443 | 0.500 |
Why?
| | Bone Marrow Cells | 2 | 2014 | 321 | 0.440 |
Why?
| | MicroRNAs | 3 | 2014 | 686 | 0.370 |
Why?
| | Genome, Human | 2 | 2014 | 420 | 0.370 |
Why?
| | Rhabdoid Tumor | 2 | 2025 | 102 | 0.360 |
Why?
| | Cell Cycle Proteins | 5 | 2022 | 630 | 0.330 |
Why?
| | Cell Proliferation | 9 | 2025 | 2507 | 0.330 |
Why?
| | Aging | 1 | 2020 | 1969 | 0.300 |
Why?
| | Proto-Oncogene Proteins c-myc | 2 | 2025 | 167 | 0.300 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2025 | 934 | 0.290 |
Why?
| | Apoptosis | 8 | 2025 | 2440 | 0.270 |
Why?
| | Neoplastic Stem Cells | 2 | 2025 | 409 | 0.240 |
Why?
| | Nuclear Proteins | 3 | 2017 | 740 | 0.230 |
Why?
| | SMARCB1 Protein | 1 | 2025 | 34 | 0.220 |
Why?
| | Sirtuin 2 | 1 | 2025 | 28 | 0.220 |
Why?
| | Protein-Arginine N-Methyltransferases | 1 | 2025 | 25 | 0.220 |
Why?
| | Histones | 2 | 2020 | 666 | 0.210 |
Why?
| | Proto-Oncogene Proteins | 3 | 2022 | 624 | 0.210 |
Why?
| | Macrophage Activation | 1 | 2025 | 181 | 0.210 |
Why?
| | Positive Transcriptional Elongation Factor B | 1 | 2024 | 29 | 0.210 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2020 | 431 | 0.210 |
Why?
| | Phagocytosis | 1 | 2025 | 296 | 0.200 |
Why?
| | Epigenomics | 2 | 2020 | 114 | 0.190 |
Why?
| | Pyrazoles | 4 | 2022 | 517 | 0.190 |
Why?
| | Genes, myc | 2 | 2020 | 51 | 0.180 |
Why?
| | Stromal Cells | 2 | 2014 | 121 | 0.180 |
Why?
| | Transcription, Genetic | 2 | 2025 | 1454 | 0.180 |
Why?
| | Mutation | 2 | 2025 | 4075 | 0.180 |
Why?
| | Mice | 9 | 2025 | 18329 | 0.180 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 1 | 2022 | 67 | 0.170 |
Why?
| | Pyrimidinones | 2 | 2020 | 125 | 0.170 |
Why?
| | Antineoplastic Agents | 3 | 2022 | 2214 | 0.170 |
Why?
| | Radiation Tolerance | 1 | 2022 | 103 | 0.170 |
Why?
| | Down-Regulation | 2 | 2014 | 618 | 0.160 |
Why?
| | Transcriptional Elongation Factors | 1 | 2020 | 39 | 0.150 |
Why?
| | Brain Stem Neoplasms | 1 | 2020 | 87 | 0.150 |
Why?
| | Astrocytoma | 1 | 2020 | 130 | 0.150 |
Why?
| | Chromatin | 2 | 2020 | 553 | 0.150 |
Why?
| | Deoxycytidine | 1 | 2020 | 220 | 0.140 |
Why?
| | Lysine | 1 | 2020 | 305 | 0.140 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2022 | 534 | 0.130 |
Why?
| | Animals | 10 | 2025 | 38030 | 0.130 |
Why?
| | Macrophages | 1 | 2025 | 1507 | 0.130 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2022 | 1149 | 0.130 |
Why?
| | Argonaute Proteins | 2 | 2014 | 32 | 0.130 |
Why?
| | RNA, Messenger | 3 | 2014 | 2803 | 0.130 |
Why?
| | Cell Differentiation | 2 | 2025 | 2046 | 0.120 |
Why?
| | Checkpoint Kinase 1 | 1 | 2016 | 27 | 0.120 |
Why?
| | Pteridines | 1 | 2016 | 22 | 0.120 |
Why?
| | Radiation-Sensitizing Agents | 1 | 2016 | 43 | 0.120 |
Why?
| | Immunophenotyping | 1 | 2017 | 319 | 0.120 |
Why?
| | Humans | 20 | 2025 | 145475 | 0.120 |
Why?
| | Ependymoma | 1 | 2017 | 176 | 0.110 |
Why?
| | Tumor Suppressor Proteins | 1 | 2017 | 321 | 0.110 |
Why?
| | Serrate-Jagged Proteins | 1 | 2014 | 27 | 0.100 |
Why?
| | Jagged-1 Protein | 1 | 2014 | 22 | 0.100 |
Why?
| | Wnt-5a Protein | 1 | 2014 | 24 | 0.100 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2014 | 56 | 0.100 |
Why?
| | Immunoprecipitation | 1 | 2014 | 148 | 0.100 |
Why?
| | NF-kappa B | 1 | 2017 | 666 | 0.100 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2014 | 530 | 0.100 |
Why?
| | Cellular Microenvironment | 1 | 2014 | 93 | 0.100 |
Why?
| | Wnt Proteins | 1 | 2014 | 133 | 0.100 |
Why?
| | Calcium-Binding Proteins | 1 | 2014 | 221 | 0.090 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2014 | 376 | 0.090 |
Why?
| | Biomarkers, Tumor | 2 | 2016 | 1321 | 0.090 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2014 | 552 | 0.080 |
Why?
| | Cell Line | 2 | 2014 | 2823 | 0.080 |
Why?
| | Molecular Targeted Therapy | 1 | 2014 | 439 | 0.080 |
Why?
| | Cerebellum | 1 | 2012 | 224 | 0.080 |
Why?
| | Chemokine CXCL12 | 1 | 2010 | 86 | 0.080 |
Why?
| | Base Sequence | 1 | 2014 | 2170 | 0.080 |
Why?
| | Molecular Sequence Data | 1 | 2014 | 2883 | 0.070 |
Why?
| | Tumor Cells, Cultured | 2 | 2025 | 886 | 0.070 |
Why?
| | Child, Preschool | 3 | 2020 | 11853 | 0.070 |
Why?
| | Child | 4 | 2025 | 22707 | 0.070 |
Why?
| | Female | 4 | 2025 | 78845 | 0.070 |
Why?
| | Endothelial Cells | 1 | 2014 | 874 | 0.070 |
Why?
| | Membrane Proteins | 1 | 2014 | 1164 | 0.060 |
Why?
| | Transcription Factors | 1 | 2014 | 1734 | 0.060 |
Why?
| | Cyclin-Dependent Kinase 9 | 1 | 2025 | 18 | 0.060 |
Why?
| | CD47 Antigen | 1 | 2025 | 42 | 0.060 |
Why?
| | CRISPR-Cas Systems | 1 | 2025 | 166 | 0.050 |
Why?
| | Epigenesis, Genetic | 2 | 2020 | 679 | 0.050 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2016 | 749 | 0.050 |
Why?
| | Cell Survival | 2 | 2016 | 1100 | 0.050 |
Why?
| | Carcinogenesis | 1 | 2025 | 228 | 0.050 |
Why?
| | G2 Phase Cell Cycle Checkpoints | 1 | 2022 | 44 | 0.040 |
Why?
| | Radiation, Ionizing | 1 | 2022 | 86 | 0.040 |
Why?
| | DNA Repair | 1 | 2024 | 254 | 0.040 |
Why?
| | Gene Expression Regulation | 1 | 2010 | 2597 | 0.040 |
Why?
| | 3' Untranslated Regions | 2 | 2012 | 149 | 0.040 |
Why?
| | Cell Cycle | 2 | 2014 | 598 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2022 | 239 | 0.040 |
Why?
| | Teratoma | 1 | 2022 | 124 | 0.040 |
Why?
| | RNA Polymerase II | 1 | 2024 | 350 | 0.040 |
Why?
| | Quinazolines | 1 | 2022 | 266 | 0.040 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 1 | 2022 | 280 | 0.040 |
Why?
| | Piperazines | 1 | 2022 | 375 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2022 | 611 | 0.040 |
Why?
| | Sulfonamides | 1 | 2022 | 583 | 0.030 |
Why?
| | Benzodiazepinones | 1 | 2016 | 18 | 0.030 |
Why?
| | Enzyme Inhibitors | 1 | 2020 | 820 | 0.030 |
Why?
| | Prognosis | 2 | 2016 | 4316 | 0.030 |
Why?
| | Urea | 1 | 2016 | 85 | 0.030 |
Why?
| | Thiophenes | 1 | 2016 | 117 | 0.030 |
Why?
| | Transcriptional Activation | 1 | 2017 | 372 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2020 | 2188 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2016 | 767 | 0.030 |
Why?
| | Cisplatin | 1 | 2016 | 345 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 969 | 0.030 |
Why?
| | Azepines | 1 | 2014 | 105 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 777 | 0.020 |
Why?
| | DNA Damage | 1 | 2016 | 437 | 0.020 |
Why?
| | Up-Regulation | 1 | 2016 | 847 | 0.020 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2014 | 337 | 0.020 |
Why?
| | Rapamycin-Insensitive Companion of mTOR Protein | 1 | 2012 | 27 | 0.020 |
Why?
| | Male | 1 | 2020 | 72843 | 0.020 |
Why?
| | Cathepsin B | 1 | 2012 | 17 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2017 | 1246 | 0.020 |
Why?
| | Triazoles | 1 | 2014 | 187 | 0.020 |
Why?
| | Mice, Nude | 1 | 2014 | 679 | 0.020 |
Why?
| | Cyclin-Dependent Kinase 6 | 1 | 2012 | 49 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 977 | 0.020 |
Why?
| | Colorado | 1 | 2022 | 4554 | 0.020 |
Why?
| | Blotting, Western | 1 | 2014 | 1179 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2012 | 506 | 0.020 |
Why?
| | Neural Stem Cells | 1 | 2012 | 168 | 0.020 |
Why?
| | CD146 Antigen | 1 | 2010 | 38 | 0.020 |
Why?
| | Chemotaxis | 1 | 2010 | 122 | 0.020 |
Why?
| | Pyrimidines | 1 | 2014 | 530 | 0.020 |
Why?
| | Cell Separation | 1 | 2010 | 305 | 0.020 |
Why?
| | Hematopoiesis | 1 | 2010 | 193 | 0.020 |
Why?
| | Repressor Proteins | 1 | 2012 | 429 | 0.020 |
Why?
| | Survival Rate | 1 | 2014 | 2090 | 0.020 |
Why?
| | Ligands | 1 | 2010 | 665 | 0.020 |
Why?
| | Genomics | 1 | 2014 | 825 | 0.020 |
Why?
| | Carrier Proteins | 1 | 2012 | 728 | 0.020 |
Why?
| | Cell Movement | 1 | 2012 | 959 | 0.020 |
Why?
| | Brain | 1 | 2020 | 2947 | 0.020 |
Why?
| | Protein Kinase Inhibitors | 1 | 2014 | 981 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2014 | 1767 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2010 | 1162 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 1963 | 0.020 |
Why?
| | Fibroblasts | 1 | 2010 | 1025 | 0.010 |
Why?
| | Phenotype | 1 | 2012 | 3155 | 0.010 |
Why?
| | Signal Transduction | 1 | 2012 | 5216 | 0.010 |
Why?
|
|
Balakrishnan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|